Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

BACKGROUND: In LUX-Lung 7, the irreversible ErbB family blocker, afatinib, significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and objective response rate (ORR) versus gefitinib in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K. H., Lu, S., Shi, Y., Lee, D. H., Laskin, J., Kim, D.-W., Laurie, S. A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391700/
https://www.ncbi.nlm.nih.gov/pubmed/28426106
http://dx.doi.org/10.1093/annonc/mdw611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391700/
https://www.ncbi.nlm.nih.gov/pubmed/28426106
http://dx.doi.org/10.1093/annonc/mdw611

Ejemplares similares